摘要
目的研究依达拉奉对急性脑梗死(ACI)患者血清基质金属蛋白酶-9(MMP-9)水平和梗死后出血的影响。方法30例ACI患者除常规治疗外,用依达拉奉30mg加入生理盐水100ml静脉滴注,每天2次,连续7d。用酶联免疫吸附法检测ACI患者发病6h、24h、4d、2周、2个月时血清MMP-9含量;在发病两周时进行头颅CT检查;并与用常规治疗的ACI患者及其他疾病患者(对照组)进行比较。结果依达拉奉组和常规治疗组的ACI患者血清MMP-9水平在发病后6h、24h、4d、2周均显著高于对照组(均P<0.01),2个月时与对照组差异无统计学意义(均P>0.05)。依达拉奉组发病后24h血清MMP-9水平显著低于常规治疗组(P<0.01)。依达拉奉组发生脑梗死后出血2例(6.67%),常规治疗组为8例(26.67%),两组差异有统计学意义(P<0.05)。结论依达拉奉可降低ACI患者血清MMP-9水平,以及脑梗死后出血的发生率。
Objective To investigate the effects of Edaravone on level of serum matrix metallopmteinase-9 （MMP-9） and hemorrhage after infarction in patients with acute cerebral infarction （ACI）. Methods Edaravone 30 mg added with saline 100 ml were used in 30 ACI patients （in addition to conventional therapy）, twice a day, 7 d in a row. Serum MMP-9 levels were measured in patients at 6 h, 24 h, 4 d, 2 w and 2 mon after onset. Cranium CT were detected at 2 w after onset. The resauhs were compared with ACI patients of conventional therapy and patients with suffered other diseases （ control group）. Results The levels of MMP-9 in Edaravone group and the conventional therapy group at 6 h, 24 h, 4 d and 2 w after onset, were higher than those in control group（ all P 〈0.01 ）. There was no significances difference of MMP-9 level at 2 mon after onset among 3 groups. The level of MMP-9 in Edaravon group was significance lower than that in the conventional therapy group at 24 h after onset（P 〈0.01 ）. There were 2 patients suffered hemorrhage after ACI in Edaravone group （ 6.67% ） , and 8 patients in the conventional therapy group（26.67% ）. There was statistical difference between two groups. Condusions Edaravone can decrease level of serum MMP-9, and also can decreased the rate of hemorrhage after ACI.
出处
《临床神经病学杂志》
CAS
北大核心
2009年第2期136-138,共3页
Journal of Clinical Neurology
关键词
急性脑梗死
依达拉奉
基质金属蛋白酶-9
脑出血
acute cerebral infarction
Edaravone
matrix metallopmteinase-9
cerebral hemorrhage
